A Phase I Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Conditions

Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Kidney | Larynx | Liver | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs

What is the purpose of this trial?

This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0032 administered every day orally (PO) in patients with locally advanced or metastatic solid tumors. In Phase II of the study, the efficacy and safety of the combination GDC-0032 and fulvestrant will be evaluated in post-menopausal female patients with locally advanced or metastatic hormone receptor-positive breast cancer.


Participation Guidelines

Age:
Gender:
Female

Click here for detailed information about who can participate in this trial.


Sponsor:
Genentech, Inc.
Dates:
09/04/2013
Last Updated:
Study HIC#:
1306012166